Skip to content


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page

PA Consulting markets new concept to help pharmaceutical and biotechnology companies recover lost productivity

8 October 2008

PA Consulting Group, the leading international management, systems and technology consultancy, has recently launched DS2  - a new partnering initiative for pharmaceutical and biotechnology R&D involving integrated scientific services which accelerates ‘time to market’ for new medicines

For many years the pharmaceutical industry has struggled to sustain a steady flow of innovative new medicines coming to market whilst the cost of R&D has continued to rise.  The industry has invested heavily in new technologies and in-licensing agreements, but still it suffers from an apparent lack of productivity.

PA’s distributed scientific services (DS2) concept is built around a new strategic partnership model that allows pharmaceutical companies to regain their productivity in bringing new medicines to patients more quickly.  It draws on the benefits that different, but complementary, scientific organisations can bring to a partnership whilst acknowledging that they have different cultures, needs and aspirations.

‘These complex cross-organisational relationships need to be well thought out and managed, but deliver value to our clients through reducing fixed costs and increasing speed to market’ says Dr. David Pardoe, who heads the DS2 initiative for PA. 

DS2 draws on PA’s established experience in building agile virtual organisations and outsourced services in other sectors.  PA’s research and experience to date suggests companies could realise reduction in time to market of as much as 20%.
Pardoe adds:  ‘Uniquely, PA’s DS2 approach brings together the core business tools, process and sector knowledge needed to really address the issues and build strong and fruitful pharmaceutical pipelines.’

Martin Smith, Head of PA’s Technology and Healthcare Group and a Member of its Management Group, comments:

‘Our approach to delivering high quality pharmaceutical scientific services through strategic partnering utilises many of PA’s existing technologies, such as ProcServe, an e-market place solution already successfully in place within the NHS and UK Government.’

PA's healthcare capability spans technology development and delivery, and consulting services for life science companies, through to supporting the health sector on healthcare delivery and reform. 

Contact the government and public sector team

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.